Social network
Media - Staying connected to our latest news and events
Media - Staying connected to our latest news and events


Staying connected to our latest news and events

Tools content (print, share, increase/decrease text size):


    Middle area:

    Press releases 2007

    Press releases are intended to journalists, analysts and investors.

    Taxotere®-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy In Early Stage Breast Cancer

    December 13, 2007

    New anti-thrombotic compound AVE5026 shows highly significant dose response in TREK phase IIb study

    December 10, 2007

    Sanofi-aventis inaugurates first Asian development centre for pharmaceuticals in Goa, India

    December 03, 2007

    Sanofi-aventis and Astellas to restructure the joint venture activities in Japan of Fujisawa sanofi-aventis K.K.

    November 30, 2007

    Sanofi-aventis initiates a major global collaboration with Regeneron to develop and commercialize fully-human therapeutic antibodies and plans to increase its stake in Regeneron to approximately 19 %

    November 29, 2007

    Sanofi-aventis to build a vaccine facility in Shenzhen for prevention of influenza and pandemic readiness in China

    November 26, 2007

    Rimonabant - Bibliographical update

    November 16, 2007

    Rimonabant - Regulatory Update in Europe

    November 13, 2007

    Sanofi Pasteur and Acambis join forces to bring West Nile vaccine to market

    November 13, 2007

    New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort® AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis

    November 10, 2007

    Retrospective Analysis Finds that Initiation of Insulin Glargine in Patients with Type 2 Diabetes was Associated with a Lower Incidence Rate of Myocardial Infarction as Compared with NPH Insulin

    November 07, 2007

    Coarsucam™/“ASAQ” is as Effective as Coartem® in Treating Uncomplicated Malaria

    November 07, 2007

    Sanofi Pasteur initiates phase II trial of cell culture-based seasonal influenza vaccine

    November 07, 2007

    Sanofi Pasteur presents positive results of tetravalent dengue candidate vaccine

    November 06, 2007

    Good third quarter performance: increase in 2007 full-year earnings growth guidance

    October 31, 2007

    Studies Showing Significant Survival Improvement with Taxotere®-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of The New England Journal of Medicine

    October 24, 2007

    New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR® (zolpidem tartrate extended-release) tablets

    October 24, 2007

    Taxotere® receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval in the European Union for induction treatment for locally advanced Head and Neck cancer

    October 22, 2007

    Plavix® indications expanded in Japan to include patients with Acute Coronary Syndrome for whom percutaneous coronary intervention is being planned

    October 22, 2007

    Sanofi Pasteur receives FDA approval of meningococcal vaccine for children

    October 18, 2007

    Sanofi Pasteur and Institut Pasteur team up against malaria

    October 15, 2007

    New prescription allergy treatment XYZAL® (levocetirizine dihydrochloride) now available for fall allergy season in the USA

    October 02, 2007

    Taxotere® (docetaxel) granted FDA approval to treat Locally Advanced Head and Neck Cancer prior to chemoradiotherapy and surgery

    October 01, 2007

    Sanofi-aventis enters the Dow Jones Sustainability World Indexes (DJSI World)

    September 24, 2007

    Appropriate glycemic control contributes to reducing the risk of macrovascular diseases in patients with diabetes

    September 19, 2007

    Rimonabant effectively reduces visceral fat in the obese patient as confirmed by abdominal computer tomography (CT) scan

    September 19, 2007

    A promising R&D portfolio, well positioned to deliver future growth

    September 17, 2007

    Sanofi-aventis initiates Research collaboration in China in the cancer stem-cell field

    September 14, 2007

    Sanofi-aventis announces settlement of Average Wholesale Price Civil Suits with the U.S. Department of Justice relating to Anzemet®

    September 10, 2007

    The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With No Observed Pro-Arrhythmia

    September 05, 2007

    Survival Benefit of Taxotere®-Based Regimens In Patients With Non Small Cell Lung Cancer

    September 04, 2007

    New Study Findings Confirm CLEXANE®/LOVENOX® Long-Term Clinical Benefit In Patients Suffering From Acute Coronary Syndrome

    September 03, 2007

    Availability on line of the Group’s half-year financial report for 2007

    August 02, 2007

    First half: solid results in a difficult context. Plavix® recovers its position in the US, full impact expected in H2

    August 01, 2007

    Sanofi pasteur President and CEO David J. Williams to retire; Wayne Pisano named President and CEO

    July 26, 2007

    Sanofi Pasteur announces completion of construction of new U.S. influenza vaccine manufacturing facility

    July 20, 2007

    CHMP approves labelling update of Acomplia® in Europe and confirms the positive benefit-risk profile of the product except in patients suffering from ongoing major depression

    July 19, 2007

    Idraparinux shows encouraging results in the prevention of thromboembolic events in patients with atrial fibrillation

    July 11, 2007

    New study shows that extending prophylaxis with Clexane®/ Lovenox® (enoxaparin sodium injection) to 5 weeks is more effective than 10 days for reducing the risk of venous thromboembolism (VTE) in acutely ill medical patients with reduced mobility

    July 08, 2007

    Plavix® (clopidogrel bisulfate) receives priority review in Japan for supplemental new drug application (sNDA) for The treatment of acute coronary syndrome

    July 04, 2007

    Rimonabant Regulatory Update in the United States

    June 29, 2007

    Rimonabant Regulatory Update in Europe

    June 29, 2007

    Taxotere® (docetaxel) Granted FDA Priority Review for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck Prior to Chemoradiotherapy and Surgery

    June 27, 2007

    Apidra® Improved A1C In People With Type 2 Diabetes When Added to Basal Insulin And Oral Antidiabetic Treatments (BOT)

    June 24, 2007

    For any given level of HbA1c, Lantus® demonstrates less confirmed hypoglycemia over Insulin NPH

    June 23, 2007

    Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus® Lowered Free Fatty Acid Levels Equal to or Better Than Thiazolidinediones

    June 23, 2007

    Sanofi-aventis and Bristol-Myers Squibb Prevail in U.S. Plavix® Patent Litigation

    June 19, 2007

    Sanofi pasteur awarded contract to retrofit influenza vaccine facility

    June 14, 2007

    FDA Advisory Committee did not recommend approval of rimonabant (Zimulti®) for use in obese and overweight patients with associated risks factors

    June 13, 2007

    Sanofi pasteur supports WHO initiative for the establishment of an H5N1 vaccine stockpile

    June 13, 2007

    Taxotere® (docetaxel) receives Priority Review in Japan for Supplemental New Drug Application (sNDA) in prostate cancer

    June 07, 2007

    Sanofi-aventis at the 43rd annual 2007 ASCO meeting

    June 06, 2007

    Copaxone® pre-filled syringe can now be stored for up to one month at room temperature

    June 06, 2007

    Eloxatin® (oxaliplatin injection)-based chemotherapy sets new treatment benchmark in patients with metastatic colorectal cancer

    June 04, 2007

    The Eloxatin®-based regimen (FOLFOX4) significantly improved progression free survival when given before and after surgery in patients with resectable liver metastases from colorectal cancer

    June 04, 2007

    Oxford BioMedica and Sanofi-aventis report encouraging new TroVax® phase II trial results in renal cancer

    June 03, 2007

    S-1, a novel oral fluoropyrimidine, when combined with cisplatin, demonstrates significant improvement in overall survival of advanced gastric cancer patients over S-1 alone

    June 03, 2007

    FOLFOX4 (Eloxatin®-based chemotherapy) after surgery improves overall survival in patients with early (stage III) colon cancer

    June 03, 2007

    “My child matters” one-year report program shows measurable improvement in cancer care for children in developing and newly industrialized countries

    June 03, 2007

    Encouraging results of VEGF Trap (Aflibercept) highlighted at ASCO 2007 annual meeting

    June 02, 2007

    Annual General Meeting

    May 31, 2007

    FDA approves XYZAL® tablets for the treatment of seasonal and year round allergies, and chronic urticaria

    May 29, 2007

    Data to be presented at ASCO 2007 highlights sanofi-aventis commitment to oncology

    May 25, 2007

    FDA approves Lovenox® (Enoxaparin Sodium Injection) for the most severe type of heart attack

    May 18, 2007

    Sanofi-aventis calls for an effective policy against drug counterfeiting

    May 15, 2007

    Full-year guidance raised on good 2007 first-quarter results

    May 03, 2007

    FDA Approves SoloSTAR® - A New Prefilled Disposable Insulin Pen For Use With LANTUS® In People With Type 1 And Type 2 Diabetes

    April 30, 2007

    Information relating to sanofi-aventis’ Combined General Meeting of May 31, 2007

    April 26, 2007

    Acomplia® (rimonabant) is approved in Brazil for the treatment of obese patients, or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidemia

    April 26, 2007

    ACOMPLIA® (rimonabant) is reimbursed in Switzerland for the treatment of Type 2 Diabetics Overweight Patients and for the treatment of Patients with Obesity

    April 24, 2007

    The Lancet Publishes PREVAIL Study Results Showing Lovenox® Superiority Over Unfractionated Heparin For Reducing The Risk Of Venous Thromboembolism In Patients With Acute Ischemic Stroke

    April 20, 2007

    FDA Licenses First U.S. Vaccine for Humans Against Avian Influenza

    April 17, 2007

    Filing of the 2006 U.S. Form 20-F and French "Document de Référence"

    April 03, 2007

    Acomplia® (rimonabant) approved in Switzerland for the treatment of obese and overweight patients with at least one cardiovascular risk factor

    April 03, 2007

    Panaldine® commercial rights transferred from Daiichi to sanofi-aventis in Japan

    April 02, 2007

    Sanofi-aventis Announces Update To The European Summary Of Product Characteristics (SmPC) For Ketek® (telithromycin)

    March 30, 2007

    Sanofi-aventis and Oxford BioMedica Enter Global Licensing Agreement to Develop and Commercialise TroVax® For Cancer

    March 28, 2007

    Rimonabant USA: Update

    March 26, 2007

    Acomplia® (rimonabant) is now officially reimbursable in France, for the treatment of eligible obese and Type 2 diabetic patients

    March 22, 2007

    LANTUS®SoloSTAR® and APIDRA®SoloSTAR® – New Disposable Insulin Pens for People with Type 1 and Type 2 Diabetes Will Be Launched Starting April 2007 in Europe

    March 16, 2007

    Sanofi-aventis' commitment to providing "Access to Medicines" in countries in the Southern Hemisphere shows real achievements

    March 12, 2007

    New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available

    March 01, 2007

    Taxotere® (docetaxel) significantly improves the survival of patients with advanced prostate cancer

    February 23, 2007

    Sanofi pasteur to License Single Dose Japanese Encephalitis Vaccine from Acambis

    February 14, 2007

    2006: In a difficult environment, another year of growth in adjusted EPS excluding selected items

    February 13, 2007

    Rimonabant USA: Update

    February 12, 2007

    Sanofi-aventis announces update to US Prescribing Information for Ketek® (telithromycin)

    February 12, 2007

    LOVENOX® patent infringement suit decided against Sanofi-aventis

    February 09, 2007

    FDA Grants Priority Review to Lovenox® (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for additional type of heart attack

    February 06, 2007

    Positive Recommendation for Acomplia® from the Transparency Committee in France

    February 06, 2007

    "My child matters": 26 programmes launched in 16 countries to fight childhood cancers

    February 01, 2007

    FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine

    January 25, 2007

    S-1 oral anticancer agent improves patients’ survival in adjuvant gastric cancer trial versus surgery alone

    January 19, 2007

    Sanofi-aventis intends to contest in court the decision to classify Acomplia® among non-reimbursable drugs in Germany

    January 12, 2007

    New Head of Research & Development at sanofi-aventis

    January 05, 2007

    Right area:




    Filter by date


    © Sanofi 2004-2016 - All rights reserved - Update: March 12, 2015

    • Site complies with W3C WCAG 2.0 (new window, in english)